Compare Stocks: MYGN, MGTX, WVE, and SVRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGTX MeiraGTx	$13.23 +4.4%	$12.00	$6.62 ▼ $15.35	$1.22B	1.23	705,929 shs	114,585 shs
MYGN Myriad Genetics	$3.11 -2.1%	$4.92	$2.74 ▼ $8.59	$296.99M	1.69	1.71 million shs	169,828 shs
SVRA Savara	$5.30 +0.5%	$5.65	$2.92 ▼ $7.01	$1.09B	0.29	1.61 million shs	407,943 shs
WVE WAVE Life Sciences	$5.32 +2.2%	$5.88	$5.01 ▼ $21.73	$1.04B	-1.26	3.87 million shs	605,299 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGTX MeiraGTx	-2.24%	-0.94%	+1.85%	+34.79%	+51.92%
MYGN Myriad Genetics	-1.86%	-0.31%	-47.52%	-11.45%	-46.00%
SVRA Savara	-7.54%	-8.98%	-7.38%	+4.77%	+95.19%
WVE WAVE Life Sciences	-0.76%	-13.62%	-15.17%	-23.19%	-40.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGTX MeiraGTx	$13.23 +4.4%	$12.00	$6.62 ▼ $15.35	$1.22B	1.23	705,929 shs	114,585 shs
MYGN Myriad Genetics	$3.11 -2.1%	$4.92	$2.74 ▼ $8.59	$296.99M	1.69	1.71 million shs	169,828 shs
SVRA Savara	$5.30 +0.5%	$5.65	$2.92 ▼ $7.01	$1.09B	0.29	1.61 million shs	407,943 shs
WVE WAVE Life Sciences	$5.32 +2.2%	$5.88	$5.01 ▼ $21.73	$1.04B	-1.26	3.87 million shs	605,299 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGTX MeiraGTx	-2.24%	-0.94%	+1.85%	+34.79%	+51.92%
MYGN Myriad Genetics	-1.86%	-0.31%	-47.52%	-11.45%	-46.00%
SVRA Savara	-7.54%	-8.98%	-7.38%	+4.77%	+95.19%
WVE WAVE Life Sciences	-0.76%	-13.62%	-15.17%	-23.19%	-40.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MGTX MeiraGTx	2.75	Moderate Buy	$26.00	96.52% Upside
MYGN Myriad Genetics	1.83	Reduce	$5.38	73.11% Upside
SVRA Savara	2.88	Moderate Buy	$10.14	91.56% Upside
WVE WAVE Life Sciences	2.94	Moderate Buy	$22.53	323.88% Upside

Current Analyst Ratings Breakdown

Latest MYGN, MGTX, WVE, and SVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	MYGN Myriad Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00
8/3/2026	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$5.50 ➝ $3.00
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00
8/3/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	WVE WAVE Life Sciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $22.00
7/31/2026	MYGN Myriad Genetics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$6.00 ➝ $4.00
7/31/2026	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $19.00
7/31/2026	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$15.00 ➝ $12.00
7/30/2026	MYGN Myriad Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MGTX MeiraGTx	$81.39M	15.05	N/A	N/A	($0.07) per share	-189.00
MYGN Myriad Genetics	$824.50M	0.36	$3.61 per share	0.86	$3.18 per share	0.98
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A
WVE WAVE Life Sciences	$42.73M	24.51	N/A	N/A	$2.30 per share	2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MGTX MeiraGTx	-$114.20M	-$1.48	N/A	N/A	N/A	-151.12%	N/A	-54.96%	N/A
MYGN Myriad Genetics	-$365.90M	-$1.19	N/A	N/A	N/A	-13.96%	-16.09%	-8.10%	11/2/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.56	N/A	N/A	N/A	N/A	-88.25%	-67.85%	N/A
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	N/A

Latest MYGN, MGTX, WVE, and SVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
7/30/2026	Q2 2026	MYGN Myriad Genetics	-$0.0579	-$0.25	-$0.1921	-$0.46	$206.03 million	$190.70 million
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million
5/14/2026	Q1 2026	MGTX MeiraGTx	-$0.6060	-$0.57	+$0.0360	-$0.57	$17.00 million	$0.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MGTX MeiraGTx	N/A	0.55	0.55
MYGN Myriad Genetics	0.40	2.21	1.98
SVRA Savara	0.17	13.47	13.47
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MGTX MeiraGTx	67.48%
MYGN Myriad Genetics	99.02%
SVRA Savara	87.93%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
MGTX MeiraGTx	7.40%
MYGN Myriad Genetics	1.90%
SVRA Savara	5.30%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MGTX MeiraGTx	300	92.61 million	85.76 million	Optionable
MYGN Myriad Genetics	2,700	95.65 million	93.83 million	Optionable
SVRA Savara	20	205.46 million	194.07 million	Optionable
WVE WAVE Life Sciences	240	197.05 million	149.17 million	Optionable

MYGN, MGTX, WVE, and SVRA Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in Stock

3 hours ago | insidertrades.com

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 13 at 11:06 PM | marketbeat.com

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

August 13 at 11:06 PM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

August 13 at 11:06 PM | marketbeat.com

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

August 13 at 9:05 AM | 247wallst.com

Wave Life Sciences: An Fairly Valued RNA Opportunity

August 12 at 4:34 AM | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened

August 12 at 4:19 AM | marketbeat.com

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11 at 5:57 PM | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

August 11 at 2:59 PM | marketbeat.com

Wave Life Sciences Completes Redomiciliation to Delaware

August 10, 2026 | finance.yahoo.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

August 10, 2026 | marketbeat.com

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026 | globenewswire.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 10, 2026 | marketbeat.com

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

August 7, 2026 | finance.yahoo.com

WAVE Life Sciences Ltd. $WVE Shares Purchased by Renaissance Technologies LLC

August 7, 2026 | marketbeat.com

Mizuho Has Lowered Expectations for WAVE Life Sciences (NASDAQ:WVE) Stock Price

August 6, 2026 | americanbankingnews.com

HC Wainwright Has Optimistic Outlook of WVE Q3 Earnings

August 6, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB)

August 5, 2026 | theglobeandmail.com

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

August 5, 2026 | globenewswire.com

Mizuho Lowers WAVE Life Sciences (NASDAQ:WVE) Price Target to $23.00

August 4, 2026 | marketbeat.com

Wave Life Sciences to Present at Upcoming Investor Conferences

August 4, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN, MGTX, WVE, and SVRA Company Descriptions

MeiraGTx NASDAQ:MGTX

$13.23 +0.56 (+4.42%)

As of 11:18 AM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Myriad Genetics NASDAQ:MYGN

$3.10 -0.07 (-2.05%)

As of 11:18 AM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Savara NASDAQ:SVRA

$5.30 +0.03 (+0.47%)

As of 11:19 AM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

WAVE Life Sciences NASDAQ:WVE

$5.32 +0.12 (+2.21%)

As of 11:19 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MYGN, MGTX, WVE, and SVRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MYGN, MGTX, WVE, and SVRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MYGN, MGTX, WVE, and SVRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN, MGTX, WVE, and SVRA Company Descriptions

MeiraGTx NASDAQ:MGTX

Myriad Genetics NASDAQ:MYGN

Savara NASDAQ:SVRA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MYGN, MGTX, WVE, and SVRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MYGN, MGTX, WVE, and SVRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MYGN, MGTX, WVE, and SVRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN, MGTX, WVE, and SVRA Company Descriptions

MeiraGTx NASDAQ:MGTX

Myriad Genetics NASDAQ:MYGN

Savara NASDAQ:SVRA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools